Exelixis' Cotellic Fails To IMblaze A Trail In Colorectal Cancer
The failure of a Cotellic/Tecentriq combo in the IMblaze370 trial highlights Exelixis' dependence on its renal cell carcinoma drug CaboMetyx and the treatment challenges of the aggressive and difficult-to-treat disease that is metastatic colorectal cancer.
You may also be interested in...
Roche’s Tecentriq IMpower150 trial showed Tecentriq plus Avastin plus paclitaxel and carboplatin significantly improved progression free survival compared to Avastin and chemo alone; overall survival data will be coming later this year.
The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.
The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.